Image-based global networking tool connects physicians from all over the world.
Figure 1 is an online global network in which healthcare practitioners, including radiologists, can share medical cases and receive feedback in real time. Using the smartphone app or web browser version, practitioners upload an image, write a caption and tag it with a category. Healthcare providers often post images of unusual cases they need help identifying or classic presentations of a disease. After the image is reviewed by Figure 1’s moderator team, the image and caption are available for questions, comments and feedback from the medical community around the world.
Read more about Figure 1 on our partner site, radRounds.
[[{"type":"media","view_mode":"media_crop","fid":"46535","attributes":{"alt":"Figure 1","class":"media-image","id":"media_crop_4195534144437","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"5405","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":"Image courtesy of Figure 1","typeof":"foaf:Image"}}]]
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.